CH5:PA:PA-Amundi ETF MSCI Europe Healthcare UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 401.75

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

54.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.17 (-0.39%)

USD 64.67B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+2.80 (+0.58%)

USD 10.34B
WRD:PA HSBC ETFs Public Limited Compa..

+0.14 (+0.44%)

USD 9.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-0.17 (-0.07%)

USD 7.53B
HHH:PA HSBC ETFs Public Limited Compa..

+0.29 (+0.58%)

USD 6.65B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+3.55 (+0.85%)

USD 6.61B
WLD:PA Lyxor UCITS MSCI World D-EUR

+1.26 (+0.40%)

USD 6.26B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.07 (+0.43%)

USD 4.96B
500U:PA Amundi Index Solutions - Amund..

+0.63 (+0.61%)

USD 4.44B
WSRI:PA Amundi MSCI World SRI Climate ..

+0.23 (+0.24%)

USD 4.01B

ETFs Containing CH5:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.26% 78% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.26% 78% C+ 75% C
Trailing 12 Months  
Capital Gain 6.92% 40% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.92% 42% F 57% F
Trailing 5 Years  
Capital Gain 63.15% 76% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.15% 75% C 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.72% 67% D+ 65% D
Dividend Return 8.72% 64% D 64% D
Total Return N/A 18% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 8.57% 69% C- 84% B
Risk Adjusted Return 101.78% 99% N/A 98% N/A
Market Capitalization 0.06B 25% F 38% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.